Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York

SAN DIEGO, Jan. 31 Cadence Pharmaceuticals, Inc.(Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,developing and commercializing proprietary product candidates principally foruse in the hospital setting, announced today that the company's President andCEO Theodore Schroeder will present the corporate overview on Tuesday,February 5, 2008 at 4:00 pm Eastern Time (1:00 pm Pacific Time) during theMerrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conferencein New York City.

The presentation will be simultaneously webcast and can be accessed onCadence Pharmaceuticals' website at http://www.cadencepharm.com in theInvestor Relations section. A replay of the webcast will be availableapproximately three hours following the live webcasts and will be archived for14 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused onin-licensing, developing and commercializing proprietary product candidatesprincipally for use in the hospital setting. The company currently has twoPhase III product candidates in development, Acetavance(TM) (intravenousacetaminophen) for the treatment of acute pain and fever, and Omigard(TM)(omiganan pentahydrochloride 1% topical gel) for the prevention ofcatheter-related infections. For more information about Cadence's pipeline,visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,Inc.Contacts: William R. LaRue Anna Gralinska SVP & Chief Financial Officer Director, Investor Relations Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc. 858-436-1400 858-436-1452

SOURCE Cadence Pharmaceuticals, Inc.

Latest Press Release on General News

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...

Dr. Andres Bustillo Responds to Miami's Growing Interest in Facelift Procedures

In response to the growing demand for facelifts in Miami , Dr. Andres Bustillo , a renowned board-certified facial plastic surgeon, is offering advanced and time-proven techniques in f...